Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StiL NHL 1-2003: Bendamustine-Rituximab vs CHOP-Rituximab in Indolent NHL and MCL
NCT00991211Phase 3Completed
- Sponsor
- Justus Liebig University Giessen
- Start
- Jan 2004
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bendamustine in Follicular lymphoma (FL), lymphoplasmacytic lymphoma (LPL), Marginal Zone Lymphoma (MZL) and 2 more (2 arms), sponsored by Justus Liebig University Giessen. Primary endpoint: Progression-Free Survival at 3 years. Started Jan 2004; status: completed.
02
Drugs
bendamustine
03
Conditions
Follicular lymphoma (FL)lymphoplasmacytic lymphoma (LPL)Marginal Zone Lymphoma (MZL)Mantle cell lymphoma (MCL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT00991211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00991211.